Shenyang Xingqi Pharmaceutical Co., Ltd. announced on September 11 that it has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for SQ-23082 eye drops, granting permission to conduct clinical trials. The product is indicated for the treatment of ocular itching associated with allergic conjunctivitis, registered as a Class 2.1 modified new chemical drug, in the form of eye drops. The company stated that it has completed pharmaceutical studies and non-clinical pharmacological and toxicological research on SQ-23082 eye drops, with results demonstrating good safety and clinical development value. Currently, no such ophthalmic preparation is marketed domestically or internationally. The company also cautioned that pharmaceutical product development involves long cycles and multiple stages, and that clinical trial progress and outcomes remain uncertain.
Shenyang Xingqi Pharmaceutical Co LtdReceived NMPA clinical trial approval for SQ-23082 eye drops, a Class 2.1 modified new drug with no marketed equivalent, advancing its pipeline.
